Albany, NY -- (SBWIRE) -- 02/15/2019 -- Group A Streptococcus (GAS) is a type of gram-positive B-hemolytic Streptococcus bacteria. These bacteria are capable of causing a wide range of both non-invasive and invasive infections. GAS infection might spread through direct contact with skin sores or mucus of a infected person. Despite the emergence of wide range effective and safe antibiotics as a treatment regimen for GAS, infection caused by GAS is increasing significantly across the world.
However, with the use of advance molecular diagnosis kits and technologies, the progression of the infections can be slowed down to a significantly, which will ultimately reduce the recovery time of the patient. Currently, molecular diagnostic market for GAS NA test is a lucrative market venture due to high patient preference and increasing base of patients suffering from Streptococcal infections, which makes this industry a highly profitable and attractive market.
Obtain Report Details @ https://www.transparencymarketresearch.com/molecular-diagnostic-market.html
Some of the molecular diagnostic techniques generally used for group A Streptococcus (GAS) NA tests are as follows:
Rapid antigen testing techniques
Rapid chromatographic immunoassay testing techniques
In vitro diagnostic testing techniques
RT-PCR based techniques
In the geographical analysis, North America is the largest market for molecular diagnostic kits for group A Streptococcus tests owing to the high incidence rate of Streptococcal infections and diseases. According to the Centers for Disease Control and Prevention (CDC), each year, nearly 11,000 people suffer from invasive GAS infections and approximately 10 million people suffer from non-invasive GAS infections, in the U.S.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2479
However, other regions such as South East Asia, Latin America and Middle East are expected to be the promising markets in the near future. Owing to the rising disposable income among population and high adoption rate for advanced molecular diagnostics kits and technologies, these regions are expected to be the potential market in the near future.
The overall molecular diagnostic market for group A Streptococcus (GAS) NA tests is experiencing an admirable growth; due to the increasing incidence rate of group A Streptococcus infections, such as pharyngitis, tonsillitis and fever. Moreover, large base of patients affected from streptococcal infections including both geriatric population and youth is expected to drive the growth of various molecular diagnostic kits that are used for group A Streptococcus tests.
It has also been estimated that, this market is shows potential to be a lucrative and expanding field due the increasing adoption rate for advanced diagnostic technologies and services. Expected technological breakthroughs will generate abundant opportunities for molecular diagnostic kits that could be used for detecting targeted Streptococcal bacteria, which causes the infections. For instance, Japan based Otsuka Pharmaceutical Co., Ltd. launched a rapid diagnostic test kit, \"QuickNavi Strep A\" for rapid detection of beta-hemolytic group A Streptococcus on 14 April 2014.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2479
However, rise in overall healthcare expenditure, stringent reimbursement policies and high development costs are some of the market-restraining factors that might hinder the growth of molecular diagnostic kits market for group A Streptococcus (GAS) NA tests in future.
Currently, the molecular diagnostic market for Group A Streptococcus (GAS) NA tests is a highly fragmented market owing to the involvement of many established and emerging players in the market. Some of the companies involved with development and commercialization of amplification and detection platforms for performing these tests are Abbott Laboratories, Applied Biosystems, Bio-Rad Laboratories, Inc., bioMérieux, Cepheid, Inc., Digene Corporation, Otsuka Pharmaceutical Co., Ltd., Qiagen, Roche Diagnostics Corporation, Siemens AG and Stratagene Corporation (Agilent Technologies Inc.)